Article (Scientific journals)
NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma.
Corradi, M.; Chrystyn, Henry; Cosio, Borja G. et al.
2014In Expert Opinion on Drug Delivery, 11 (9), p. 1497-506
Peer Reviewed verified by ORBi
 

Files


Full Text
NEXThaler, an innovative dry powder_Corradi.pdf
Author postprint (442.42 kB)
Download
Annexes
ERRATUM_CORRADI_NEXThaler.pdf
Publisher postprint (71.32 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Administration, Inhalation; Anti-Asthmatic Agents/administration & dosage/pharmacokinetics; Asthma/drug therapy/physiopathology; Beclomethasone/administration & dosage/pharmacokinetics; Drug Combinations; Drug Delivery Systems; Dry Powder Inhalers; Ethanolamines/administration & dosage/pharmacokinetics; Humans; Lung/metabolism; Particle Size; asthma; beclometasone; dry powder inhaler; extrafine particles; formoterol; small airways
Abstract :
[en] INTRODUCTION: Airway inflammation and remodelling in asthma occur in the large airways and also in the small airways. The small airways are those < 2 mm in diameter and are significant sites of chronic asthmatic inflammation. It is important, therefore, to target the small as well as the large airways in any strategy for effective treatment of this disease. AREAS COVERED: The present review deals with the recently developed fixed dose drug combination of beclometasone dipropionate/formoterol fumarate that emits extrafine particles when delivered from an innovative dry powder inhaler (DPI), NEXThaler(R). The aim is to present the technical and clinical aspects of aerosolized drug delivery to the lungs. EXPERT OPINION: The data show that the NEXThaler DPI is an efficient device for the management of persistent asthma. The evaluation of the inhalation profiles through the NEXThaler DPI demonstrates that device activation and consistent dose delivery occurs at patient achievable inhalation flow rates, and supports the broad utility of the NEXThaler DPI in patients with asthma. Overall, all the effectiveness, efficiency and satisfaction outcomes demonstrate the NEXThaler DPI is easy to use.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Corradi, M.
Chrystyn, Henry
Cosio, Borja G.
Pirozynski, Michal
Loukides, Stelios
Louis, Renaud ;  Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Spinola, Monica
Usmani, Omar S.
Language :
English
Title :
NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma.
Publication date :
September 2014
Journal title :
Expert Opinion on Drug Delivery
ISSN :
1742-5247
eISSN :
1744-7593
Publisher :
Taylor & Francis, United Kingdom
Volume :
11
Issue :
9
Pages :
1497-506
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Un erratum a été publié. Il est joint à cette fiche. Voici sa référence : Expert Opin Drug Deliv. 2014 Nov;11(11):1827. URL : http://informahealthcare.com/doi/pdf/10.1517/17425247.2014.976738.
Available on ORBi :
since 02 February 2015

Statistics


Number of views
617 (1 by ULiège)
Number of downloads
1444 (0 by ULiège)

Scopus citations®
 
77
Scopus citations®
without self-citations
64
OpenCitations
 
67

Bibliography


Similar publications



Contact ORBi